Business Standard

Covaxin Phase-3 efficacy analysis to be made public by July: Bharat Biotech

The company is also doing phase-4 trials for real world effectiveness of the jab

Bharat Biotech, Covaxin
Premium

Photo: Shutterstock

Sohini Das Mumbai
Covaxin manufacturer Bharat Biotech said that the detailed analysis of the phase-3 clinical trial data of its Covid-19 vaccine will be made public by July. The company is also doing phase-4 trials for real world effectiveness of vaccines, reports said.

In a series of tweets, Raches Ella, project lead, Covid19 vaccines at Bharat Biotech said that the last volunteer of their phase-3 clinical trial (sample size 25,800) was vaccinated in mid-March. “Mandatory CDSCO/FDA requirement of a two-month safety follow-up for all volunteers landed us in Mid May,” Ella said. He claimed that this was the largest efficacy trial conducted in

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in